FDA regulation of cardiovascular devices and opportunities for improvement

被引：12

作者：

Dhruva, Sanket S. ^{[1
]}

Redberg, Rita F. ^{[2
]}

机构：

[1] Univ Calif Davis, Dept Internal Med, Div Cardiol, Davis, CA 95616 USA

[2] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA

来源：

JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY | 2013年 / 36卷 / 02期

关键词：

Cardiovascular devices; Cardiovascular disease; FDA; Medical device regulation; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; MEDICAL DEVICES; POSTMARKETING SURVEILLANCE; PREMARKET APPROVAL; THERAPY; TRIALS; WOMEN; OUTCOMES; FAILURE; RECALLS;

D O I：

10.1007/s10840-012-9767-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Medical devices are of increasing importance in cardiovascular disease and have made important contributions to patient care. These devices continue to evolve with increasing complexity. FDA regulation of medical devices involves increased stringency for higher risk and novel devices. However, there are some current opportunities to strengthen the FDA's pre-approval regulatory process and improve post-marketing surveillance. This article reviews FDA regulation of cardiovascular devices and offers suggestions for strengthening the process while focusing on examples relevant to cardiac electrophysiologists.

引用

页码：99 / 105

页数：7

共 50 条

[31] Reporting of Demographics & Subgroup Analyses in Premarketing Studies of FDA Approved High Risk Cardiovascular Devices, 2014-2022
Swanson, Matthew J.
Uyeki, Colin L.
Yoder, Sarah R.
Dhruva, Sanket S.
Miller, Jennifer E.
Ross, Joseph S.
MEDICAL DEVICES-EVIDENCE AND RESEARCH, 2024, 17 : 165 - 172
[32] Evaluating the FDA regenerative medicine framework: opportunities for stakeholders
Richardson, Elizabeth
Akkas, Farzana
Master, Zubin
REGENERATIVE MEDICINE, 2020, 15 (07) : 1825 - 1832
[33] Measuring Patient Preferences at the FDA Center for Devices and Radiological Health: Reflections and Projections
Webber, Christina M.
Chen, Allen L.
Gebben, David J.
Saha, Anindita
Tarver, Michelle E.
VALUE IN HEALTH, 2021, 24 (07) : 1024 - 1029
[34] RISK ASSESSMENT AND MANAGEMENT AS RELATED TO EVALUATION OF MEDICAL DEVICES - A VIEW FROM THE FDA
CALLAHAN, TJ
MARLOWE, DE
JOURNAL OF LONG-TERM EFFECTS OF MEDICAL IMPLANTS, 1993, 3 (04) : 269 - 276
[35] A REVIEW OF DESIGN FOR X METHODS FOR MEDICAL DEVICES: THE INTRODUCTION OF A DESIGN FOR FDA APPROACH
Medina, Lourdes A.
Wysk, Richard A.
Kremer, Guel E. Okudan
PROCEEDINGS OF THE ASME INTERNATIONAL DESIGN ENGINEERING TECHNICAL CONFERENCES AND COMPUTERS AND INFORMATION IN ENGINEERING CONFERENCE, 2011, VOL 9, 2012, : 849 - 861
[36] How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Samuel, Andre M.
Rathi, Vinay K.
Grauer, Jonathan N.
Ross, Joseph S.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2016, 474 (04) : 1053 - 1068
[37] SHATTUCK LECTURE Innovation, Regulation, and the FDA
Hamburg, Margaret A.
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (23) : 2228 - 2232
[38] Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities
Chaffey, Laura
Roberti, Annabell
Greaves, David R.
FRONTIERS IN PHARMACOLOGY, 2022, 13
[39] Guidelines for the prevention of cardiovascular disease in women: international challenges and opportunities
Gupta, Divya
Wenger, Nanette K.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (03) : 379 - 385
[40] Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health
Ronquillo, Jay G.
Zuckerman, Diana M.
MILBANK QUARTERLY, 2017, 95 (03) : 535 - 553

← 1 2 3 4 5 →